
BriaCell Therapeutics Corp. — Investor Relations & Filings
BriaCell Therapeutics Corp. is a clinical-stage immuno-oncology company developing a novel class of targeted cellular immunotherapies for cancer. Its lead candidate, Bria-IMT™, is a patented, off-the-shelf, cell-based therapy in a pivotal Phase 3 study for advanced metastatic breast cancer. Bria-IMT™, which has received FDA Fast Track designation, is designed to activate the patient's immune system to kill cancer cells. The company is also advancing its next-generation Bria-OTS™ platform, a personalized off-the-shelf immunotherapy that uses HLA matching to provide treatment for a broad patient population. Clinical studies for the Bria-OTS™ platform are ongoing for breast cancer, with planned expansion into prostate cancer, lung cancer, and melanoma.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K - BRIACELL THERAPEUTICS CORP. (0001610820) (Filer) | 2026-02-20 | English | |
| DEF 14A Filing | 2026-02-12 | English | |
| SCHEDULE 13G Filing | 2026-01-23 | English | |
| 8-K | 2026-01-15 | English | |
| 424B4 | 2026-01-14 | English | |
| Regulatory Filings 2026 | 2026-01-14 | English |
Browse filings by year
10 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
9 filings
| |||||
| 32895080 | 8-K - BRIACELL THERAPEUTICS CORP. (0001610820) (Filer) | 2026-02-20 | English | ||
| 30911158 | DEF 14A Filing | 2026-02-12 | English | ||
| 30911060 | SCHEDULE 13G Filing | 2026-01-23 | English | ||
| 12788475 | 8-K | 2026-01-15 | English | ||
| 12788477 | 424B4 | 2026-01-14 | English | ||
| 12788476 | Regulatory Filings 2026 | 2026-01-14 | English | ||
| 12788480 | S-1MEF | 2026-01-14 | English | ||
| 12788478 | Regulatory Filings 2026 | 2026-01-13 | English | ||
| 12788479 | 8-A12B | 2026-01-13 | English | ||
|
2025
6 filings
| |||||
| 12788481 | 8-K | 2025-12-29 | English | ||
| 12788482 | FWP | 2025-12-23 | English | ||
| 12788483 | S-1 | 2025-12-23 | English | ||
| 12788484 | 10-Q | 2025-12-11 | English | ||
| 12788485 | 8-K | 2025-11-29 | English | ||
| 12788486 | Major Shareholding Notification 2025 | 2025-11-07 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Annovis Bio, Inc.
A clinical-stage drug platform company developing therapies…
|
ANVS | US | Professional, scientific and te… |
|
AnorMED Inc.
Developed small molecule therapeutics for serious diseases,…
|
— | CA | Professional, scientific and te… |
|
ANTEOTECH LTD
Develops nanoglue technology for life sciences and lithium-…
|
ADO | AU | Professional, scientific and te… |
|
Anthem Biosciences Limited
Integrated CRAMS organization for drug discovery, developme…
|
ANTHEM | IN | Professional, scientific and te… |
|
APPLIED DNA SCIENCES INC
Develops and manufactures DNA-based technologies for geneti…
|
APDN | US | Professional, scientific and te… |
|
Aprea Therapeutics, Inc.
Clinical-stage biopharma developing cancer therapeutics via…
|
APRE | US | Professional, scientific and te… |
|
AprilBio Co.,Ltd.
Develops long-acting biologic drugs for autoimmune diseases…
|
397030 | KR | Professional, scientific and te… |
|
Aptahem AB
A clinical-stage biotech developing aptamer-based drugs for…
|
APTA | SE | Professional, scientific and te… |
|
APTAMER GROUP PLC
Develops custom affinity binders for research, diagnostics,…
|
APTA | GB | Professional, scientific and te… |
|
Aptevo Therapeutics Inc.
Clinical-stage biotech developing antibody-based immunother…
|
APVO | US | Professional, scientific and te… |
BriaCell Therapeutics Corp. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34987/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34987 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34987 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34987 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34987}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for BriaCell Therapeutics Corp. (id: 34987)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.